About Us

Text size
view with small font size
view with medium font size
view with large font size


A passion for innovation

One of the world’s most innovative developers of advanced therapeutics, Kyowa Kirin Pharmaceutical Development, Inc. (KKD) is dedicated to improving lives. It’s that simple…and that profound.  Every effort, every investment, reinforces its ongoing innovative efforts in promising technologies.

KKD’s most valuable asset is its people. Through the unparalleled dedication and skill of its team, KKD offers its customers and partners extraordinary potential for success.

When global leaders Kyowa Hakko Group and Kirin Group merged in 2008, they created KKD’s parent company Kyowa Kirin USA Holdings, Inc. (referred to as Kyowa Kirin).  As a wholly owned subsidiary of Kyowa Kirin, KKD is poised to leverage, not only the strengths, insights and innovative spirit of both industry pioneers, but their impressive scientific pipeline, to accelerate the development of biopharmaceuticals.  Additionally, KKD benefits from the synergistic relationship it has with fellow Kyowa Kirin US subsidiary, BioWa, Inc., exclusive worldwide licensor of Potelligent® technology, which dramatically enhances the antibody-dependent cellular cytotoxicity (ADCC) of antibodies, and Complegent™ high complement dependent cytotoxicity (CDC) technology.

A concern for the environment

At a time when the world faces climate and environmental challenges, and greater demands on a decreasing supply of petroleum fuels, expectations for more sustainable business practices have increased.  Without question, KKD feels strongly that protecting the environment and the world’s resources is a top priority. To that end, KKD promotes and maintains a vigorous recycling program at all of its offices.  As a company, we work to reduce waste, from office paper to computer equipment, and provide recycling receptacles for glass, plastics and paper. Where choices can be made, KKD endeavors to choose wisely to minimize its impact on the environment.